IPQ Inside the global regulatory dialogue

Industry Comments on FDA’s Draft Data Integrity Guidance Reveal Regulatory Challenges

Jul 29th, 2016

Please Log in to print the full article

The comments do speak to the industry appetite for more extensive guidance on the regulatory expectations for handling data integrity. However, FDA’s intention in the guidance was not to provide a comprehensive DI review, but...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications